Targeting immune inhibitory antigens such as PD-1, PD-L1 and CTLA-4 with either nivolumab, pembrolizumab or ipilimumab have been tested in clinical studies focused on GBM, showing promising results in terms of both safety/feasibility and anti-tumor activity (117–121). The gene discussed is CTLA4; the disease is neoplasm.